The thesis
channel-pullback is a trend-following mean-reversion hybrid. It buys pullbacks toward the lower regression channel or volume support within confirmed uptrends, then exits at the upper channel or resistance. The edge it's betting on is timing: ride established trends, but enter on weakness rather than chasing strength. It runs live against a 24-name large-cap universe spanning tech, financials, healthcare, staples, and energy — AAPL and NVDA alongside JNJ, KO, XOM, and CAT.
Recent activity
The strategy trades daily and actively. Over the last week its scheduled runs executed cleanly — mostly 2–3 fills per day with few rejections (the 2026-09-29 run was the exception, rejecting both candidates). Paper equity has drifted down modestly, from roughly $11,079 on 09-28 to $10,848.54 on 10-02, with cash around $1,700.
The trade tape shows the style in action. A clean win: NVDA bought at $224.16 on 09-25 and sold at $230.06 on 09-28. Less flattering: CVX was sold at $206.95 on 10-01 and re-bought at $207.21 the very next day — the kind of whipsaw that high turnover invites. Recent entries (PFE, JNJ, KO, MA) lean defensive and value-oriented, consistent with pullback hunting in staples and healthcare.
Backtest and validation
Over 451 days the backtest returned 7.62% (CAGR 4.19%), growing a $10k book to $10,761.52. The character of that return matters: a 39.39% win rate across 137 trades means the strategy loses more often than it wins and relies on winners being materially larger than losers. The Sharpe of 0.40 is modest, and max drawdown reached 14.83%. Turnover is extreme at 2,311% — this book recycles its capital many times over.
Critically, validation did not pass. Four walk-forward folds split 3 positive, 1 negative — but that one negative fold (2025-01-22 to 2025-07-05) was severe: -11.42% at a -1.70 Sharpe. Fold 3 then roared back +20.68% at a 3.86 Sharpe. That dispersion is the whole story. The deflated Sharpe ratio (DSR) of 0.196 — which penalises for the 7 trials run — is the likely gate failure, even though the probabilistic Sharpe (PSR) sits at a healthier 0.702. Out-of-sample, the most recent fold returned a tamer +3.63%.
Strengths and risks
The strengths are real: a coherent, well-understood thesis; disciplined asymmetric exits that overcome a sub-coin-flip hit rate; and consistent live execution. But the risks are equally clear. A 39% win rate demands tight loss control that fold 2 shows can break down in a hostile regime. Seven trials plus a low DSR flag genuine overfitting concern. And 2,300% turnover means the edge must survive real-world frictions that a $1-per-trade fee model flatters.
Verdict: a promising idea with an honest failing grade. Keep it live and paper-only, and watch whether the next out-of-sample window looks more like fold 3 or fold 2.